Framework for animal testing, Pg2

Key Highlights:

• The UK's Medicines and Healthcare products Regulatory Agency (MHRA) will introduce a framework by the end of 2026 allowing drug makers to seek review of drug data developed without animal testing before applying for approval.
• The draft guidance aims to reduce reliance on animal studies in drug development.
• The U.S. FDA has also issued draft guidance encouraging companies to reduce animal testing and adopt alternatives.

Detailed Insights:

• The MHRA's framework aligns with a global trend towards limiting animal testing in the pharmaceutical industry.
• This initiative could accelerate the development and approval of new drugs by reducing the time and cost associated with animal studies.
• The framework may encourage innovation in alternative testing methods, such as cell-based assays and computer modeling.

Key Concepts Involved:

• Animal Testing: The use of non-human animals in experiments to assess the safety and efficacy of drugs and other products.
• Drug Development: The process of researching, testing, and formulating new medications for human use.
• Medicines Regulator: A government agency responsible for overseeing the safety, efficacy, and quality of pharmaceutical products.